Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699504 · ClinicalTrials.gov registry record · Phase 1
Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers
A Phase 1 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT00699504 is a Phase 1 study that has completed, run by The Medicines Company. The registered enrollment target is 67 participants.
The verdict
NCT00699504, a Phase 1 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.
Interventions
- DRUG placebo
- DRUG moxifloxacin
- DRUG cangrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00699504
The ClinicalTrials.gov registry entry for NCT00699504 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Medicines Company, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00699504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00699504 about?
NCT00699504 is a clinical study titled "Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers". To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram (ECG) at therapeutic and supratherapeutic doses.
What is the current status of trial NCT00699504?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2008-06. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00699504?
The interventions under investigation include: placebo (DRUG), moxifloxacin (DRUG), cangrelor (DRUG).
Who is sponsoring clinical trial NCT00699504?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.